• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Compass Therapeutics Inc.

    11/27/23 4:10:14 PM ET
    $CMPX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $CMPX alert in real time by email
    SC 13G 1 p23-2863sc13g.htm COMPASS THERAPEUTICS, INC.

     

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
     
    SCHEDULE 13G
     
    Under the Securities Exchange Act of 1934
    (Amendment No. )*
     

    Compass Therapeutics, Inc.

    (Name of Issuer)
     

    Common Stock, par value $0.0001 per share

    (Title of Class of Securities)
     

    20454B104

    (CUSIP Number)
     

    November 16, 2023

    (Date of Event Which Requires Filing of This Statement)
     
     
    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
     
    ¨ Rule 13d-1(b)
    ý Rule 13d-1(c)
    ¨ Rule 13d-1(d)
     
    (Page 1 of 11 Pages)

     

    ______________________________

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

    CUSIP No. 20454B10413GPage 2 of 11 Pages

     

    1

    NAME OF REPORTING PERSON

    Adage Capital Partners, L.P.

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) ¨

    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Delaware

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH:
    5

    SOLE VOTING POWER

    0

    6

    SHARED VOTING POWER

    7,211,800

    7

    SOLE DISPOSITIVE POWER

    0

    8

    SHARED DISPOSITIVE POWER

    7,211,800

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    7,211,800

    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    5.66%

    12

    TYPE OF REPORTING PERSON

    PN

           

     

     

     

     

    CUSIP No. 20454B10413GPage 3 of 11 Pages

     

    1

    NAME OF REPORTING PERSON

    Adage Capital Partners GP, L.L.C.

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) ¨

    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Delaware

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH:
    5

    SOLE VOTING POWER

    0

    6

    SHARED VOTING POWER

    7,211,800

    7

    SOLE DISPOSITIVE POWER

    0

    8

    SHARED DISPOSITIVE POWER

    7,211,800

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    7,211,800

    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    5.66%

    12

    TYPE OF REPORTING PERSON

    OO

           

     

     

     

    CUSIP No. 20454B10413GPage 4 of 11 Pages

     

    1

    NAME OF REPORTING PERSON

    Adage Capital Management, L.P.

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) ¨

    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Delaware

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH:
    5

    SOLE VOTING POWER

    0

    6

    SHARED VOTING POWER

    7,211,800

    7

    SOLE DISPOSITIVE POWER

    0

    8

    SHARED DISPOSITIVE POWER

    7,211,800

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    7,211,800

    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    5.66%

    12

    TYPE OF REPORTING PERSON

    PN, IA

           

     

     

     

    CUSIP No. 20454B10413GPage 5 of 11 Pages

     

    1

    NAME OF REPORTING PERSON

    Robert Atchinson

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) ¨

    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    United States

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH:
    5

    SOLE VOTING POWER

    0

    6

    SHARED VOTING POWER

    7,211,800

    7

    SOLE DISPOSITIVE POWER

    0

    8

    SHARED DISPOSITIVE POWER

    7,211,800

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    7,211,800

    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    5.66%

    12

    TYPE OF REPORTING PERSON

    IN

           

     

     

     

     

    CUSIP No. 20454B10413GPage 6 of 11 Pages

     

    1

    NAME OF REPORTING PERSON

    Phillip Gross

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) ¨

    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    United States

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH:
    5

    SOLE VOTING POWER

    0

    6

    SHARED VOTING POWER

    7,211,800

    7

    SOLE DISPOSITIVE POWER

    0

    8

    SHARED DISPOSITIVE POWER

    7,211,800

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    7,211,800

    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    5.66%

    12

    TYPE OF REPORTING PERSON

    IN

           

     

     

     

     

    CUSIP No. 20454B10413GPage 7 of 11 Pages

     

    Item 1(a). NAME OF ISSUER
      The name of the issuer is Compass Therapeutics, Inc. (the “Company”).

     

    Item 1(b). ADDRESS OF ISSUER’S PRINCIPAL EXECUTIVE OFFICES
      The Company’s principal executive offices are located at 80 Guest St., Suite 601, Boston, Massachusetts 02135.

     

    Item 2(a). NAME OF PERSON FILING
      This statement is filed by:

     

      (i) Adage Capital Partners, L.P., a Delaware limited partnership (“ACP”) with respect to the Common Stock directly owned by it;
       
      (ii) Adage Capital Partners GP, L.L.C., a limited liability company organized under the laws of the State of Delaware (“ACPGP”), as general partner of ACP with respect to the Common Stock directly owned by ACP;
       
      (iii) Adage Capital Management, L.P., a Delaware limited partnership (“ACM”), as the investment manager of ACP, with respect to the Common Stock directly owned by ACP;
       
      (iv) Robert Atchinson (“Mr. Atchinson”), as (1) managing member of Adage Capital Advisors, L.L.C., a limited liability company organized under the laws of the State of Delaware (“ACA”), managing member of ACPGP and (2) managing member of Adage Capital Partners LLC, a Delaware limited liability company (“ACPLLC”), general partner of ACM, with respect to the Common Stock directly owned by ACP; and
       
      (v) Phillip Gross (“Mr. Gross”), as (1) managing member of ACA, managing member of ACPGP and (2) managing member of ACPLLC, general partner of ACM, with respect to the Common Stock directly owned by ACP.

     

      The foregoing persons are hereinafter sometimes collectively referred to as the “Reporting Persons.”  Any disclosures herein with respect to persons other than the Reporting Persons are made on information and belief after making inquiry to the appropriate party.
       
      The filing of this statement should not be construed in and of itself as an admission by any Reporting Person as to beneficial ownership of the securities reported herein.

     

    Item 2(b). ADDRESS OF PRINCIPAL BUSINESS OFFICE OR, IF NONE, RESIDENCE
      The address of the business office of each of the Reporting Persons is 200 Clarendon Street, 52nd Floor, Boston, Massachusetts 02116.

     

    Item 2(c). CITIZENSHIP
      ACP is a limited partnership organized under the laws of the State of Delaware.  ACPGP and ACA are limited liability companies organized under the laws of the State of Delaware.  Messrs. Gross and Atchinson are citizens of the United States.

     

    CUSIP No. 20454B10413GPage 8 of 11 Pages

     

    Item 2(d). TITLE OF CLASS OF SECURITIES
      Common Stock, par value $0.0001 per share (the “Common Stock”).

     

    Item 2(e). CUSIP NUMBER
      20454B104

     

    Item 3. IF THIS STATEMENT IS FILED PURSUANT TO Rules 13d-1(b), OR 13d-2(b) OR (c), CHECK WHETHER THE PERSON FILING IS A:

     

      (a) ¨ Broker or dealer registered under Section 15 of the Act;
      (b) ¨ Bank as defined in Section 3(a)(6) of the Act;
      (c) ¨ Insurance company as defined in Section 3(a)(19) of the Act;
      (d) ¨ Investment company registered under Section 8 of the Investment Company Act of 1940;
      (e) ¨ An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E);
      (f) ¨

    An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F);

     

      (g) ¨

    A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G);

     

      (h) ¨

    A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act;

     

      (i) ¨

    A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act;

     

      (j) ¨ A non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J);
      (k) ¨ Group, in accordance with Rule 13d-1(b)(1)(ii)(K).

     

      If filing as a non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J), please
      specify the type of institution: Not applicable.

     

    Item 4. OWNERSHIP
      The information required by Items 4(a) – (c) is set forth in Rows (5) – (11) of the cover page for each Reporting Person hereto and is incorporated herein by reference for each such Reporting Person.
       
      The percentage set forth in this Schedule 13G is calculated based upon 127,486,326 shares of Common Stock outstanding as of November 3, 2023, as reported in the Company’s Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2023 filed with the Securities and Exchange Commission on November 9, 2023.

     

     

    CUSIP No. 20454B10413GPage 9 of 11 Pages

     

    Item 5. OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS
      Not applicable.

     

    Item 6. OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON
      Not applicable.

     

    Item 7. IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY OR CONTROL PERSON
      Not applicable.

     

    Item 8. IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP
      Not applicable.

     

    Item 9. NOTICE OF DISSOLUTION OF GROUP
      Not applicable.

     

    Item 10. CERTIFICATION
      Each of the Reporting Persons hereby makes the following certification:
       
      By signing below each Reporting Person certifies that, to the best of his or its knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

     

    CUSIP No. 20454B10413GPage 10 of 11 Pages

    SIGNATURES

    After reasonable inquiry and to the best of his or its knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct.

    DATE: November 27, 2023

     

    ADAGE CAPITAL PARTNERS, L.P.  
    By:  Adage Capital Partners GP, L.L.C.,  
    its general partner  
       
    By:  Adage Capital Advisors, L.L.C.,  
    its managing member  
       
    /s/ Robert Atchinson  
    Name:  Robert Atchinson  
    Title: Managing Member  
       
    ADAGE CAPITAL PARTNERS GP, L.L.C.  
    By:  Adage Capital Advisors, L.L.C.,  
    its managing member  
       
    /s/ Robert Atchinson  
    Name:  Robert Atchinson  
    Title: Managing Member  
       
    ADAGE CAPITAL MANAGEMENT, L.P.  
    By: Adage Capital Partners LLC,  
    its general partner  
       
    /s/ Robert Atchinson  
    Name:  Robert Atchinson  
    Title: Managing Member  
       
    /s/ Robert Atchinson  
    ROBERT ATCHINSON, individually  
       
    /s/ Phillip Gross  
    PHILLIP GROSS, individually  

     

     

    CUSIP No. 20454B10413GPage 11 of 11 Pages

    EXHIBIT 1

    JOINT FILING AGREEMENT
    PURSUANT TO RULE 13d-1(k)

    The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without the necessity of filing additional joint filing agreements. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the information concerning him or it contained herein and therein, but shall not be responsible for the completeness and accuracy of the information concerning the others, except to the extent that he or it knows or has reason to believe that such information is inaccurate.

     

    DATE: November 27, 2023

     

    ADAGE CAPITAL PARTNERS, L.P.  
    By:  Adage Capital Partners GP, L.L.C.,  
    its general partner  
       
    By:  Adage Capital Advisors, L.L.C.,  
    its managing member  
       
    /s/ Robert Atchinson  
    Name:  Robert Atchinson  
    Title: Managing Member  
       
    ADAGE CAPITAL PARTNERS GP, L.L.C.  
    By:  Adage Capital Advisors, L.L.C.,  
    its managing member  
       
    /s/ Robert Atchinson  
    Name:  Robert Atchinson  
    Title: Managing Member  
       
    ADAGE CAPITAL MANAGEMENT, L.P.  
    By: Adage Capital Partners LLC,  
    its general partner  
       
    /s/ Robert Atchinson  
    Name:  Robert Atchinson  
    Title: Managing Member  
       
    /s/ Robert Atchinson  
    ROBERT ATCHINSON, individually  
       
    /s/ Phillip Gross  
    PHILLIP GROSS, individually  

     

    Get the next $CMPX alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CMPX

    DatePrice TargetRatingAnalyst
    7/1/2025$9.00Outperform
    Raymond James
    4/2/2025$6.00Market Perform → Outperform
    Leerink Partners
    2/24/2025$12.00Buy
    Guggenheim
    2/19/2025$12.00Overweight
    Piper Sandler
    12/23/2024$32.00Buy
    D. Boral Capital
    11/15/2024$5.00 → $4.00Outperform → Market Perform
    Leerink Partners
    9/16/2024$5.00Neutral → Buy
    Ladenburg Thalmann
    1/31/2023$8.00Buy
    Jefferies
    More analyst ratings

    $CMPX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Compass Therapeutics Announces Pricing of Upsized $120 Million Public Offering

    BOSTON, Aug. 12, 2025 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. ("Compass") (NASDAQ:CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced the pricing of an underwritten public offering of 33,290,000 shares of its common stock at a price to the public of $3.00 per share and pre-funded warrants to purchase up to an aggregate of 6,710,000 shares of its common stock at a price to the public of $2.9999 per pre-funded warrant to purchase one share of the common stock, which represents the per share public offering price for the common stock less the $0.0001 per share exercise p

    8/12/25 10:28:04 PM ET
    $CMPX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Compass Therapeutics Announces Proposed Public Offering

    BOSTON, Aug. 12, 2025 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. ("Compass") (NASDAQ:CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced the launch of an underwritten public offering of its common stock and, in lieu of common stock to certain investors, pre-funded warrants to purchase shares of its common stock. All shares of common stock and pre-funded warrants to be sold in the offering will be offered by Compass. Compass also intends to grant the underwriters a 30-day option to purchase additional shares of its common stock offered in the public offering under the sam

    8/12/25 4:01:00 PM ET
    $CMPX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Compass Therapeutics Reports 2025 Second Quarter Financial Results and Provides Corporate Update

    In the ongoing Phase 2/3 study of tovecimig (DLL4 x VEGF-A bispecific antibody) in patients with advanced biliary tract cancer, fewer deaths have been observed than originally projected. We believe this may suggest that tovecimig could be affecting overall survival in the patient population. As a result, the analysis of the secondary endpoints, including overall survival, is now expected in Q1 2026.In the ongoing Phase 1 dose-escalation study of CTX-8371 (PD-1 x PD-L1 bispecific antibody) in patients treated in the post-checkpoint inhibitor setting, two deep and confirmed partial responses have been observed to date. A patient with non-small cell lung cancer had a 100% reduction in target le

    8/11/25 7:00:00 AM ET
    $CMPX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $CMPX
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13D/A filed by Compass Therapeutics Inc.

    SCHEDULE 13D/A - Compass Therapeutics, Inc. (0001738021) (Subject)

    8/15/25 5:28:04 PM ET
    $CMPX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Compass Therapeutics Inc.

    SCHEDULE 13G/A - Compass Therapeutics, Inc. (0001738021) (Subject)

    8/14/25 4:15:07 PM ET
    $CMPX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Compass Therapeutics Inc.

    SCHEDULE 13G/A - Compass Therapeutics, Inc. (0001738021) (Subject)

    8/14/25 10:49:59 AM ET
    $CMPX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $CMPX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CHIEF EXECUTIVE OFFICER Schuetz Thomas J. bought $21,100 worth of shares (10,000 units at $2.11), increasing direct ownership by 0.15% to 6,480,825 units (SEC Form 4)

    4 - Compass Therapeutics, Inc. (0001738021) (Issuer)

    5/27/25 3:24:21 PM ET
    $CMPX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Gordon Carl L sold $5,678,571 worth of shares (3,571,428 units at $1.59) (SEC Form 4)

    4 - Compass Therapeutics, Inc. (0001738021) (Issuer)

    4/11/25 7:37:43 PM ET
    $CMPX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Orbimed Advisors Llc sold $5,678,571 worth of shares (3,571,428 units at $1.59) (SEC Form 4)

    4 - Compass Therapeutics, Inc. (0001738021) (Issuer)

    4/11/25 7:24:24 PM ET
    $CMPX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $CMPX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Raymond James resumed coverage on Compass Therapeutics with a new price target

    Raymond James resumed coverage of Compass Therapeutics with a rating of Outperform and set a new price target of $9.00

    7/1/25 8:17:42 AM ET
    $CMPX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Compass Therapeutics upgraded by Leerink Partners with a new price target

    Leerink Partners upgraded Compass Therapeutics from Market Perform to Outperform and set a new price target of $6.00

    4/2/25 8:43:28 AM ET
    $CMPX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Guggenheim initiated coverage on Compass Therapeutics with a new price target

    Guggenheim initiated coverage of Compass Therapeutics with a rating of Buy and set a new price target of $12.00

    2/24/25 7:07:23 AM ET
    $CMPX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $CMPX
    Leadership Updates

    Live Leadership Updates

    View All

    Compass Therapeutics Appoints Biopharmaceutical Industry Leader Barry Shin as Chief Financial Officer

    BOSTON, Dec. 10, 2024 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (NASDAQ:CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced the appointment of Barry Shin as Chief Financial Officer, as of December 9, 2024. Mr. Shin is a veteran biopharmaceutical leader with over 20 years of experience as a finance and operations executive, investment banker, and corporate advisor. "We are delighted to welcome Barry to Compass during this pivotal and exciting time for the company," said Thomas Schuetz, MD, PhD, CEO of Compass and Vice Chairman of the Board of Directors. "We have severa

    12/10/24 8:00:00 AM ET
    $CMPX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Compass Therapeutics Announces CEO Transition

    BOSTON, May 28, 2024 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (NASDAQ:CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced that its Board of Directors has appointed Thomas Schuetz, M.D., Ph.D., President of Research and Development and Vice Chair of the Board of Directors of the Company, as President and Chief Executive Officer of the Company, effective May 28, 2024. Vered Bisker-Leib, Ph.D., M.B.A., has stepped down as Chief Executive Officer and as a member of the Board of Directors of the Company, effective May 28, 2024. Dr. Bisker-Leib will continue to be available

    5/28/24 4:10:20 PM ET
    $CMPX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Compass Therapeutics Reports First Quarter Financial Results and Provides Corporate Update

    Initiated patient enrollment in a U.S. Phase 2/3 study of CTX-009 (DLL4 /VEGF-A bispecific antibody) in patients with advanced biliary tract cancers (BTC). Top line data is expected in the first half of 2024Continue to enroll in a U.S. Phase 2 study of CTX-009 in patients with advanced colorectal cancer (CRC). Initial data expected in the third quarter of 2023Presented results of a Phase 2 study of CTX-009 in combination with paclitaxel in patients with BTC at the 2023 ASCO GI Cancers SymposiumExpanded the management team with the appointment of Minori Rosales, M.D. PhD, as Senior Vice President & Head of Clinical DevelopmentAppointed Richard Lindahl, M.B.A., EVP & CFO of Emergent BioSolutio

    5/4/23 8:30:00 AM ET
    $CMPX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $CMPX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CHIEF EXECUTIVE OFFICER Schuetz Thomas J. bought $21,100 worth of shares (10,000 units at $2.11), increasing direct ownership by 0.15% to 6,480,825 units (SEC Form 4)

    4 - Compass Therapeutics, Inc. (0001738021) (Issuer)

    5/27/25 3:24:21 PM ET
    $CMPX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Gen Counsel & Corporate Sec Anderman Jonathan bought $30,800 worth of shares (20,000 units at $1.54), increasing direct ownership by 2,000% to 21,000 units (SEC Form 4)

    4 - Compass Therapeutics, Inc. (0001738021) (Issuer)

    4/8/25 9:30:55 AM ET
    $CMPX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    CHIEF ACCOUNTING OFFICER Lerner Neil bought $28,400 worth of shares (20,000 units at $1.42), increasing direct ownership by 7% to 320,000 units (SEC Form 4)

    4 - Compass Therapeutics, Inc. (0001738021) (Issuer)

    4/8/25 9:25:57 AM ET
    $CMPX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $CMPX
    Financials

    Live finance-specific insights

    View All

    Compass Therapeutics Reports 2025 Second Quarter Financial Results and Provides Corporate Update

    In the ongoing Phase 2/3 study of tovecimig (DLL4 x VEGF-A bispecific antibody) in patients with advanced biliary tract cancer, fewer deaths have been observed than originally projected. We believe this may suggest that tovecimig could be affecting overall survival in the patient population. As a result, the analysis of the secondary endpoints, including overall survival, is now expected in Q1 2026.In the ongoing Phase 1 dose-escalation study of CTX-8371 (PD-1 x PD-L1 bispecific antibody) in patients treated in the post-checkpoint inhibitor setting, two deep and confirmed partial responses have been observed to date. A patient with non-small cell lung cancer had a 100% reduction in target le

    8/11/25 7:00:00 AM ET
    $CMPX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Compass Therapeutics to Present Second Quarter Financial Results and Provide Business Update on August 11, 2025

    BOSTON, Aug. 08, 2025 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (NASDAQ:CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics, will release its financial results for the quarter ended June 30, 2025 and host a webcast and conference call to provide an update on the ongoing tovecimig Phase 2/3 study, clinical data for CTX-8371 and preclinical data for CTX-10726, on Monday, August 11, 2025, at 8:00 a.m. ET. Call Details: Date: Monday, August 11, 2025 Time: 8:00 AM ET Webcast: https://viavid.webcasts.com/starthere.jsp?ei=1727543&tp_key=955a2c2f4d Dial-In: 1-877-407-9716 (US), 1-201-493-6779 (International), 13754954 (Co

    8/8/25 4:01:00 PM ET
    $CMPX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Compass Therapeutics to Host Conference Call Highlighting Clinical Data from CTX-009

    Call scheduled for Wednesday, May 4, 2022 at 8:00 a.m. ET Key Opinion Leader to Participate BOSTON, May 03, 2022 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (NASDAQ:CMPX), a clinical-stage biopharmaceutical company developing proprietary antibody-based therapeutics to treat cancer, today announced that it will host a webinar on Wednesday, May 4, 2022 at 8:00 a.m. ET to review clinical data from its ongoing Phase 2 clinical trial assessing CTX-009. A Key Opinion Leader will join management for the discussion. Webinar Details:   Date:  May 04, 2022   Time: 8:00 a.m. ET   Webcast: Registration Link   Replay availability: A replay will be available on the Compass website for 6 months. Abo

    5/3/22 4:01:00 PM ET
    $CMPX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $CMPX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Compass Therapeutics Inc.

    SC 13G/A - Compass Therapeutics, Inc. (0001738021) (Subject)

    11/14/24 10:00:35 AM ET
    $CMPX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G filed by Compass Therapeutics Inc.

    SC 13G - Compass Therapeutics, Inc. (0001738021) (Subject)

    8/2/24 4:15:57 PM ET
    $CMPX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13D/A filed by Compass Therapeutics Inc. (Amendment)

    SC 13D/A - Compass Therapeutics, Inc. (0001738021) (Subject)

    3/22/24 4:59:51 PM ET
    $CMPX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care